iBio, Inc. (NYSE:IBIO), a Healthcare Biotechnology corporation, saw its stock exchange 0.4233 common shares, a lower amount when compared to its 10-day trading volume of 18.27M.
iBio, Inc. (IBIO) stock traded at $0.4233, up 0.1513 cents or +55.62% on the day. Based on this we can see some traders are either waiting on the sidelines to get involved or perhaps some are taking profits.
In response to investor and media inquiries regarding their initiatives to address the coronavirus outbreak, iBio, Inc. (NYSE AMERICAN:IBIO) and Beijing CC-Pharming Ltd., today announced their collaboration to develop and test a new 2019-nCoV vaccine to be manufactured using iBio’s FastPharming System™. The companies are expediting work as predictions about spread of the disease continue to worsen.
Total Revenue for iBio, Inc. (IBIO) is $2.08M, Gross Profit is $2.02M and the EBITDA is $-13.65M.
iBio, Inc. (IBIO) Key Technicals:
The average 10-day trading volume of iBio, Inc. (IBIO) is 18.27M compared to 8.91M over the last 3 months which indicates a lower amount in trading activity. At the time of writing this article, iBio, Inc. (IBIO) has a 50-day moving average of $0.2582 and a 200-day moving average of $0.4178. These moving averages are popular technical figures that investors use to analyze price trends of iBio, Inc. (IBIO).
Approximately 1.87% of the shares of the company are sold short from investors betting the shares may trade lower. The beta value on iBio, Inc. (IBIO) stock is 0.61, indicating its 16.43% to 15.91% more volatile than the overall marketplace.
Technically, IBIO’s short term support levels are around $0.27, $0.19 and $0.11 on the downside. IBIOs short term resistance levels are $1.14, $0.71 and $0.66 on the upside.
Based on technical analysis, IBIO has short term rating of Bullish (0.29), Intermediate rating of Bullish (0.46) and the long-term rating of Neutral (0.17) giving it an overall rating of Bullish (0.31).
IBIO is trading 766.00% off its 52 week low at $0.05 and -69.07% off its 52 week high of $1.40. Performance wise, IBIO stock has recently shown investors -2.86% a lower amount in a week, -8.11% a lower amount in a month and 67.80% an increase in the past quarter.
Furthermore, iBio, Inc. (IBIO) has shown a return of 9.24% since the beginning of the year.
iBio, Inc. (IBIO) Key Details:
iBio, Inc. (IBIO) is a micro-cap company with a market cap value of $25.113M. IBIO insiders hold roughly 53.07% of the shares.
There are currently 27.84M shares in the float and 63.27M shares outstanding. There are 1.87% shares short in IBIOs float.
The industry rank for iBio, Inc. (IBIO) is 74 out of 254 ranking it at the Top 29% .
iBio, Inc. (IBIO) Fundamental Research:
IBIO last 2 years revenues have increased from $2,018 to $2,081 showing an uptrend.
The book value per share (mrq) is -0.09 and cash per share (mrq) is 0.03.
About iBio, Inc. (IBIO):
Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company’s hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.